KPP
UTMD icon

Kings Path Partners’s Utah Medical Products UTMD Stock Holding History

Kings Path Partners’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,509
Closed -$523K – 294
2024
Q4 		$523K Hold
8,509
– – 0.22% 97
2024
Q3 		$569K Hold
8,509
– – 0.24% 92
2024
Q2 		$568K Buy
+8,509
New +$579K 0.27% 91

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Kings Path Partners's UTMD Position: Q1 2025 in Review

Kings Path Partners sold out of Utah Medical Products (UTMD) in Q1 2025, closing a stake of 8,509 shares — an estimated $523K sold.

Kings Path Partners first reported a position in UTMD in Q2 2024 and held it in 3 quarters. The position peaked at $569K in Q3 2024. 109 funds tracked by Wall St. Rank hold UTMD as of Q1 2025.

  • Kings Path Partners reported no remaining Utah Medical Products position as of Q1 2025 after selling out during the quarter.
  • Kings Path Partners sold 8,509 Utah Medical Products shares in Q1 2025, an estimated $523K.
  • Kings Path Partners first reported a position in Utah Medical Products in Q2 2024 and held it in 3 quarters.
  • Kings Path Partners's Utah Medical Products position peaked at $569K in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2025.

Based on Kings Path Partners's 13F filing for Q1 2025, filed 4 Apr 2025.